Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
+5
Published on August 21
Wegovy's approval has created the first-ever approved treatment pathway for MASH, opening a multi-billion dollar market that affects millions. These companies are positioned to follow this precedent with their own innovative therapies.
These firms are developing next-generation treatments for liver disease and metabolic disorders, representing some of the most promising advances in modern medicine. Early positioning could capture significant value as treatments progress through trials.
With Wegovy's success establishing regulatory precedent, these companies now have a clearer route to approval for similar treatments. This reduces development uncertainty and could accelerate time to market for promising candidates.
Following Wegovy's groundbreaking FDA approval for liver disease treatment, we've identified a significant opportunity in metabolic disorder therapies. This approval validates GLP-1 agonists beyond diabetes and weight loss, opening a multi-billion dollar market for conditions that previously lacked approved treatments.
These biopharmaceutical companies operate at the cutting edge of medical research, developing innovative therapies for liver fibrosis and related metabolic conditions. The regulatory pathway is now clearer following Wegovy's success, potentially reducing development risks for similar treatments.
Each company was specifically selected for their promising drug candidates that could follow Wegovy's newly established precedent. Our analysts identified firms with strong pipelines targeting liver disease and metabolic disorders, positioning them to capitalise on this emerging market opportunity.
Summary of total market capitalisation and breakdown for investor interpretation.
NVO: $180.85B
MDGL: $9.58B
ETNB: $2.20B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+264.23%
On average, analysts expect assets in this group to grow 264.23% over the next year.
13 of 14 assets in this group are rated Buy by professional analysts.
